Skip to content

Type 1 diabetes — immunopathogenesis

TL;DR — T1D arises from an interaction among adaptive immunity, β-cell vulnerability, innate/exocrine pancreatic changes, and host genetics rather than from a single linear attack (Atkinson 2023, PMID 37478842). Islet autoantibodies predict disease but T cells are the principal effectors implicated in β-cell killing; human pancreatic pathology shows sparse, lobular, age-dependent insulitis rather than uniform inflammation (Pugliese 2016, PMID 27411434; Rodriguez-Calvo 2018, PMID 30293191). Residual β cells and C-peptide commonly persist after diagnosis, proving that destruction is incomplete and heterogeneous (Shields 2018, PMID 29880650). Clinical responses to anti-CD3, B-cell depletion, costimulation blockade, and β-cell-protective verapamil show that both immune and β-cell-intrinsic processes are modifiable, but no intervention yet reliably produces durable immune tolerance (Herold 2019, PMID 31180194; Forlenza 2023, PMID 36826844).

A network model

Component Evidence in human T1D Interpretation
HLA-restricted adaptive immunity Strong genetic association; autoreactive T cells; immunotherapy responses Central causal axis
Islet autoantibodies Precede symptoms and predict progression Biomarkers of adaptive autoimmunity
β-cell stress ER stress, altered antigen presentation, heterogeneous survival Possible amplifier and therapeutic target
Innate immunity Cytokine and myeloid-cell signals Contributor, not a standalone explanation
Exocrine pancreas Structural and inflammatory abnormalities Part of broader pancreatic phenotype; causality uncertain
Viral exposures Molecular detection and temporal associations Plausible trigger in subsets; not necessary or sufficient alone

The “pathogenic symphony” formulation replaces the older picture of passive β cells awaiting a uniform autoimmune assault. It integrates immune dysregulation, β-cell stress and identity, and exocrine-pancreas abnormalities (Atkinson 2023, PMID 37478842).

Antigen recognition and adaptive immunity

High-risk HLA class II molecules shape presentation of islet antigens to CD4 T cells, while HLA class I pathways expose β-cell peptides to cytotoxic CD8 T cells. Insulin, GAD65, IA-2, ZnT8, and modified or hybrid peptides are prominent antigenic targets. The autoantibodies against several of these antigens are exceptionally useful for staging, but transfer of ordinary islet autoantibodies has not been shown to reproduce human β-cell destruction; they are best treated as reporters of a broader immune response (Atkinson 2023, PMID 37478842).

CD8 T cells are enriched in insulitic lesions, and CD4 T cells coordinate inflammatory and regulatory programs. Regulatory T-cell quantity alone does not explain disease; phenotype, tissue localization, and suppressive function matter. B cells serve as antigen-presenting and immune-organizing cells in addition to making antibody, consistent with transient C-peptide preservation after rituximab in new-onset disease (Gupta 2012, PMID 22703858).

Human insulitis is patchy

Histology is constrained by scarce tissue, variable disease duration, and the fact that biopsy is not routine. Donor-organ programs and archived pancreata show that insulitis is often focal and lobular, can affect insulin-containing islets while sparing neighboring islets, and is more readily found near diagnosis in younger people (Pugliese 2016, PMID 27411434; Rodriguez-Calvo 2018, PMID 30293191).

Observation Consequence for models
Few inflamed islets in many specimens A biopsy or section can miss disease
Insulin-containing and insulin-deficient islets coexist Loss is asynchronous
Younger-onset tissue often shows more active lesions Pathology differs by age and tempo
Residual insulin-positive cells persist Replacement and regeneration targets remain plausible
Exocrine changes accompany endocrine pathology T1D may involve more than islets alone

Methods for pancreatic histology have standardized how immune infiltrates and endocrine markers are evaluated, but sampling remains the decisive limitation (Willcox 2016, PMID 26801316).

β cells as active participants

β cells carry an unusually high secretory load. Cytokines, viral sensing, oxidative stress, and endoplasmic-reticulum stress can alter insulin processing, antigen generation, HLA class I expression, and cell survival. These changes may make stressed cells more visible to immunity and may create neoepitopes (Atkinson 2023, PMID 37478842).

β-cell heterogeneity offers a possible explanation for selective survival: cells differ in maturity, stress responses, proliferation, and antigen presentation. The clinical fact that C-peptide decline has an early rapid and later stable phase is consistent with changing vulnerability or immune intensity, although trajectory data alone cannot choose the mechanism (Shields 2018, PMID 29880650).

Verapamil provides a human perturbation of the β-cell-stress hypothesis. In adults and children with recent-onset T1D, verapamil preserved stimulated C-peptide relative to placebo/usual care (Ovalle 2018, PMID 29988125; Forlenza 2023, PMID 36826844). Conversely, near-normal glycemia through intensive closed-loop treatment did not preserve C-peptide in newly diagnosed children, arguing that metabolic rest alone is insufficient (McVean 2023, PMID 36826834).

What treatment experiments teach

Intervention Primary target Mechanistic lesson
Teplizumab CD3/T-cell signaling T-cell modulation can delay stage 3 and preserve C-peptide
Rituximab CD20 B cells B cells contribute beyond antibody production
Abatacept CD80/86 costimulation T-cell activation pathway is biologically active; stage-1 clinical endpoint was not met
Low-dose ATG Broad T-cell depletion/modulation C-peptide effects can persist, but depletion is not tolerance
Verapamil β-cell stress pathway Non-immune β-cell protection can preserve function
Tight closed-loop glycemia Metabolic load Glycemic normalization alone did not stop immune loss

Teplizumab delayed clinical onset in stage-2 relatives and preserved C-peptide in new-onset children (Herold 2019, PMID 31180194; Ramos 2023, PMID 37861217). Abatacept did not significantly delay progression from stage 1 in its primary analysis despite immune effects (Russell 2023, PMID 36920087). Five-year follow-up after low-dose ATG/GCSF documents persistence of treatment-associated immunologic and metabolic signals but does not establish drug-free tolerance (Lin 2021, PMID 33632742). A 2025 six-person open-label “immune education” pilot preserved median C-peptide AUC at 91–100% of baseline at 12 months, but it fell to 44–56% at five years; the result is hypothesis-generating rather than evidence of durable tolerance (Piemonti 2025, PMID 41438972).

Viruses and innate sensing

A 2023 systematic review and meta-analysis found enteroviral nucleic acids or proteins associated with islet autoimmunity or T1D across controlled observational studies, supporting an association but not a universal causal pathway (Isaacs 2023, PMID 37390839). TEDDY found respiratory infections temporally associated with initiation of autoimmunity (Lönnrot 2017, PMID 28770319). Timing, tissue specificity, strain, host genotype, and reverse causation remain difficult to separate.

Viral hypotheses are compatible with heterogeneity: infection could initiate autoimmunity in some, accelerate an existing process in others, or simply mark an immune state. A successful antiviral or vaccine prevention trial would provide stronger causal evidence than association studies.

Why tolerance is hard

By the time multiple autoantibodies appear, antigen spreading and memory-cell formation may make a single target insufficient. Immune depletion can transiently reset populations without teaching durable antigen-specific tolerance. Meanwhile β-cell stress can continue to provide antigen and danger signals. This predicts that combinations may need to address immune effector cells, regulation/tolerance, inflammation, and β-cell survival simultaneously (Atkinson 2023, PMID 37478842).

The safety threshold is stage-dependent. More immune risk may be acceptable in established, unstable disease than in an asymptomatic child with uncertain timing. That constraint shapes prevention trial design as strongly as biological plausibility.

What human tissue can and cannot establish

The canonical lesion is sparser than textbook diagrams imply. A review of human material estimated insulitis in about 10% of islets in children within one year of diagnosis, based on only roughly 150 informative cases gathered over a century (In't Veld 2014, PMID 25005747). A negative section cannot exclude focal disease, donor illness can alter tissue, and cross-sectional donors cannot directly reveal sequence.

Observation Scale/result Inference Residual uncertainty
Recent-onset insulitis ~10% of islets in affected children Attack is focal and asynchronous Sampling determines visibility
Multimodal islet atlas ~80,000 transcriptomes, ~7 million cytometry cells, ~1 million imaged cells Multiple pancreatic compartments participate Cross-sectional donor selection
IFN-exposed β cells IFN-α/γ signatures most closely matched T1D islets Interferons amplify danger sensing Ex vivo dose and timing
HLA immunopeptidome IFN-α favored HLA-B and alternative peptides Inflammation changes what CD8 cells see Initiation versus amplification

The atlas covered 24 T1D, autoantibody-positive, and non-diabetic donors and found a ductal state resembling tolerogenic dendritic cells—evidence of attempted regulation as well as injury (Fasolino 2022, PMID 35228745). It does not prove that this state protects β cells.

Interferon–presentation loop

Deep RNA sequencing found that IFN-α and IFN-γ altered human β-cell transcription more than IL-1β or TNF-α and produced signatures correlated with T1D donor islets; ZNFX1 was an induced dsRNA sensor (Coomans de Brachène 2024, PMID 38409439). IFN-α preferentially increased HLA-B display, expanded peptides from alternative splicing, protein cis-splicing, and post-translational modification, and activated HLA-B-restricted CD8 cells (Carré 2025, PMID 39824805).

  1. Viral or endogenous double-stranded RNA activates innate sensing.
  2. Interferon increases antigen processing and HLA class I display.
  3. Stressed β cells present a broader peptide repertoire.
  4. Cytotoxic recognition generates more inflammation and antigen.

The initiating signal need not be viral. β-cell-specific loss of ADAR RNA editing generated endogenous dsRNA, interferon activation, insulitis, and β-cell failure in a mouse model with corroborating human-islet signatures (Knebel 2024, PMID 38128529). This is a plausible virus-independent mimic, not proof that ADAR failure initiates human disease.

Neoantigens and incomplete tolerance

New antigen classes include post-translationally modified peptides, hybrid peptides, alternative reading-frame products, and splice-derived sequences. Human autoreactive T cells recognize some, offering a route by which secretory stress exposes antigens poorly represented during thymic selection (Purcell 2019, PMID 31010879). Whether neoantigens break tolerance or broaden an established response remains unresolved.

A protective INS rs3842752 allele created an IRE1α cleavage motif: during ER stress, insulin mRNA decayed faster, human β cells showed lower stress and less defective-ribosomal-product neoantigen, and transplanted islets functioned better in mice (van Tienhoven 2025, PMID 40112799). This supplies a concrete β-cell-intrinsic mechanism, while the in-vivo human causal effect remains to be quantified.

Competing causal emphases

Emphasis Strongest evidence What it does not explain alone
Autoreactive T cells Islet CD8 enrichment; anti-CD3 efficacy Why a particular β cell or time is vulnerable
B cells Transient C-peptide preservation after rituximab Persistence after B-cell reconstitution
β-cell fragility Stress pathways and verapamil signal Organ-specific adaptive memory
Viral triggering Prospective timing and molecular meta-analysis Nonviral cases and heterogeneity
Network model Single-cell and perturbation data integrate compartments Difficult to falsify without longitudinal tissue

These explanations are compatible rather than exclusive. Decisive studies need longitudinal peripheral sampling tied to rare tissue observations and intervention-specific pharmacodynamic readouts.

Peripheral single-cell studies add breadth but not direct access to the target organ. A cross-sectional analysis of 46 people with stage 3 T1D and 31 controls identified widespread transcriptional dysregulation across immune-cell types and proposed molecular subtypes (Honardoost 2024, PMID 38539228). A smaller discovery study identified a SIGLEC-1-positive monocyte population with a strong interferon signature and validated the signal in additional samples (Guo 2024, PMID 38349399). These findings fit β-cell–immune cross-talk models (Peters 2019, PMID 31309537), but treatment, disease duration, batch effects, and tissue–blood discordance prevent peripheral clusters from being treated as pancreatic mechanism by themselves.

Open questions

  • Are surviving β cells intrinsically resistant, dedifferentiated and hidden, or simply located in less-inflamed lobules? Human histology shows heterogeneity but cannot yet adjudicate (Rodriguez-Calvo 2018, PMID 30293191).
  • Which enteroviral association is causal, and would an antiviral or vaccine intervention change seroconversion or stage progression? (Isaacs 2023, PMID 37390839)
  • Why does verapamil preserve C-peptide when near-normal closed-loop glycemia does not? (Forlenza 2023, PMID 36826844; McVean 2023, PMID 36826834)
  • Which combination can create durable antigen-specific tolerance without chronic immunosuppression? Current immune interventions mostly delay decline (Herold 2019, PMID 31180194; Russell 2023, PMID 36920087).

References

  1. Atkinson MA, et al. The pathogenic “symphony” in type 1 diabetes. Cell Metab. 2023;35:1500-1518. PMID 37478842
  2. Pugliese A. Insulitis in the pathogenesis of type 1 diabetes. Pediatr Diabetes. 2016;17 Suppl 22:31-36. PMID 27411434
  3. Rodriguez-Calvo T, et al. Pancreas Pathology During the Natural History of Type 1 Diabetes. Curr Diab Rep. 2018;18:124. PMID 30293191
  4. Willcox A, et al. Histology of Type 1 Diabetes Pancreas. Methods Mol Biol. 2016;1433:105-117. PMID 26801316
  5. Shields BM, et al. C-Peptide Decline in Type 1 Diabetes Has Two Phases. Diabetes Care. 2018;41:1486-1492. PMID 29880650
  6. Gupta S. Immunotherapies in diabetes mellitus type 1. Med Clin North Am. 2012;96:621-634. PMID 22703858
  7. Ovalle F, et al. Verapamil and beta cell function in adults with recent-onset type 1 diabetes. Nat Med. 2018;24:1108-1112. PMID 29988125
  8. Forlenza GP, et al. Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes. JAMA. 2023;329:990-999. PMID 36826844
  9. McVean J, et al. Effect of Tight Glycemic Control on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes. JAMA. 2023;329:980-989. PMID 36826834
  10. Herold KC, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019;381:603-613. PMID 31180194
  11. Ramos EL, et al. Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes. N Engl J Med. 2023;389:2151-2161. PMID 37861217
  12. Russell WE, et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk. Diabetes Care. 2023;46:1005-1013. PMID 36920087
  13. Lin A, et al. Low-Dose ATG/GCSF in Established Type 1 Diabetes: A Five-Year Follow-up Report. Diabetes. 2021;70:1123-1129. PMID 33632742
  14. Isaacs SR, et al. Enteroviruses and risk of islet autoimmunity or type 1 diabetes. Lancet Diabetes Endocrinol. 2023;11:578-592. PMID 37390839
  15. Lönnrot M, et al. Respiratory infections are temporally associated with initiation of type 1 diabetes autoimmunity. Diabetologia. 2017;60:1931-1940. PMID 28770319
  16. In't Veld P. Insulitis in human type 1 diabetes: a comparison between patients and animal models. Semin Immunopathol. 2014;36:569-579. PMID 25005747
  17. Fasolino M, et al. Single-cell multi-omics analysis of human pancreatic islets reveals novel cellular states in type 1 diabetes. Nat Metab. 2022;4:284-299. PMID 35228745
  18. Coomans de Brachène A, et al. Interferons are key cytokines acting on pancreatic islets in type 1 diabetes. Diabetologia. 2024;67:908-927. PMID 38409439
  19. Carré A, et al. Interferon-α promotes HLA-B-restricted presentation of antigens in human pancreatic β-cells. Nat Commun. 2025;16:765. PMID 39824805
  20. Knebel UE, et al. Disrupted RNA editing in beta cells mimics early-stage type 1 diabetes. Cell Metab. 2024;36:48-61.e6. PMID 38128529
  21. Purcell AW, et al. The Evolving Landscape of Autoantigen Discovery and Characterization in Type 1 Diabetes. Diabetes. 2019;68:879-886. PMID 31010879
  22. van Tienhoven R, et al. Genetic protection from type 1 diabetes resulting from accelerated insulin mRNA decay. Cell. 2025;188:2407-2416.e9. PMID 40112799
  23. Peters L, et al. Islet-immune interactions in type 1 diabetes: the nexus of beta-cell destruction. Clin Exp Immunol. 2019;198:326-340. PMID 31309537
  24. Honardoost MA, et al. Immune dysregulation and molecular subtypes revealed by single-cell RNA-seq in T1D. Genome Med. 2024;16:45. PMID 38539228
  25. Guo M, et al. SIGLEC-1-positive interferon-signature monocytes in recent-onset T1D. Diabetologia. 2024;67:623-640. PMID 38349399
  26. Piemonti L, et al. Induction of immune education in type 1 diabetes through controlled allogeneic islet rejection at onset: a monocentric open-label pilot study. EClinicalMedicine. 2025;90:103685. PMID 41438972